The US FDA approved Epidiolex® (cannabidiol, or CBD) for certain seizure syndromes in June, and today the DEA listed it as a Schedule V controlled substance (the least restrictive). This action will greatly facilitate clinical use and clinical trials of CBD in the U.S. Note that there is little evidence at this point that CBD […]
We were happy to participate in the first-ever study of a dopamine D1 blocking drug in children with TS. The study results were recently published, showing evidence of benefit without substantial side effects. Click here for additional background information, a summary of the results, and a link to the publication. (https://goo.gl/gh5YfM)
This web page describes a recent publication from Wash.U. and several other research sites on factors associated with successful tic suppression in 99 children and adolescents with a tic disorder.
Here’s a brief summary of what we know about cannabis and related drugs for treatment of tics.